|
|
|
|
||
Re: CMS expanding CAR T to medicare up to $1.5M - Hospitals will love thisThe Centers for Medicare & Medicaid Services, CMS, is part of the Department of Health and Human Services (HHS). https://www.cms.gov/About-CMS/About-CMS.html _______________________________________________________________________________________________________________________________ CMS said the proposal, announced Friday, would require Medicare to cover the cancer treatment when it is offered in a CMS-approved registry or clinical study, as long as data is collected from the patients for at least two years after treatment. CMS said it plans to use the information to decide what treatments are most beneficial to patients and which CAR-T therapies to fund in the future. _______________________________________________________________________________________________________________________________ "Today's proposed coverage decision would improve access to this therapy while deepening CMS's understanding of how patients in Medicare respond to it, so the agency can ensure that it is paying for CAR T-cell therapy for cases in which the benefits outweigh the risks," said CMS Administrator Seema Varma in a statement." _______________________________________________________________________________________________________________________________________________________________________ YESCARTA is in 68 centers and 12 in EU ______________________________________________________________________________________________________________ They have no competition from Kymirah - which can't manufacture their own CAR T - and were told by the FDA they could not sell commercially, until they can prove they can manufacture. Thus the poor sales over the last year, and NVS management covering up. ______________________________________________________________________________________________________________________________________________ YESCARTA has no manufacturing problems. |
return to message board, top of board |